Income Statement Veeva Systems Inc.
Equities
VEEV
US9224751084
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.61 USD | +0.52% |
|
-9.22% | -17.30% |
| 02-03 | BioDlink Modernizes Quality Management with Successful Go-Live of Veeva QMS | CI |
| 01-14 | Veeva Systems Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 01:30 PM |
| Fiscal Period: January | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.47B | 1.85B | 2.16B | 2.36B | 2.75B | |||||
Total Revenues | 1.47B | 1.85B | 2.16B | 2.36B | 2.75B | |||||
Cost of Goods Sold, Total | 409M | 504M | 609M | 677M | 700M | |||||
Gross Profit | 1.06B | 1.35B | 1.55B | 1.69B | 2.05B | |||||
Selling General & Admin Expenses, Total | 384M | 460M | 566M | 628M | 657M | |||||
R&D Expenses | 294M | 382M | 520M | 629M | 693M | |||||
Other Operating Expenses, Total | 678M | 842M | 1.09B | 1.26B | 1.35B | |||||
Operating Income | 378M | 505M | 459M | 429M | 696M | |||||
Interest And Investment Income | 15.86M | 14.73M | 45.86M | 134M | 208M | |||||
Net Interest Expenses | 15.86M | 14.73M | 45.86M | 134M | 208M | |||||
Currency Exchange Gains (Loss) | 2.28M | -714K | 591K | 124K | -3.27M | |||||
Other Non Operating Income (Expenses) | 1.15M | - | 572K | - | 611K | |||||
EBT, Excl. Unusual Items | 397M | 520M | 506M | 563M | 902M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | -3.08M | -7.2M | 2.98M | 24.82M | 22.62M | |||||
Legal Settlements | - | - | - | - | -5M | |||||
EBT, Incl. Unusual Items | 394M | 512M | 509M | 588M | 919M | |||||
Income Tax Expense | 14M | 84.92M | 21.39M | 62.32M | 205M | |||||
Earnings From Continuing Operations | 380M | 427M | 488M | 526M | 714M | |||||
Net Income to Company | 380M | 427M | 488M | 526M | 714M | |||||
Net Income - (IS) | 380M | 427M | 488M | 526M | 714M | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 380M | 427M | 488M | 526M | 714M | |||||
Net Income to Common Excl. Extra Items | 380M | 427M | 488M | 526M | 714M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.52 | 2.79 | 3.14 | 3.27 | 4.41 | |||||
Basic EPS - Continuing Operations | 2.52 | 2.79 | 3.14 | 3.27 | 4.41 | |||||
Basic Weighted Average Shares Outstanding | 151M | 153M | 155M | 161M | 162M | |||||
Net EPS - Diluted | 2.36 | 2.63 | 3 | 3.22 | 4.32 | |||||
Diluted EPS - Continuing Operations | 2.36 | 2.63 | 3 | 3.22 | 4.32 | |||||
Diluted Weighted Average Shares Outstanding | 161M | 162M | 162M | 163M | 165M | |||||
Normalized Basic EPS | 1.65 | 2.12 | 2.04 | 2.19 | 3.48 | |||||
Normalized Diluted EPS | 1.54 | 2 | 1.95 | 2.15 | 3.41 | |||||
Supplemental Items | ||||||||||
EBITDA | 407M | 533M | 488M | 462M | 736M | |||||
EBITA | 398M | 524M | 478M | 448M | 715M | |||||
EBIT | 378M | 505M | 459M | 429M | 696M | |||||
EBITDAR | 420M | 547M | 504M | 478M | 750M | |||||
Total Revenues (As Reported) | 1.47B | 1.85B | 2.16B | 2.36B | 2.75B | |||||
Effective Tax Rate - (Ratio) | 3.55 | 16.58 | 4.2 | 10.6 | 22.32 | |||||
Current Domestic Taxes | 11.87M | 66.01M | 140M | 156M | 307M | |||||
Current Foreign Taxes | 2.82M | 7.84M | 8.51M | 12.16M | 10.9M | |||||
Total Current Taxes | 14.7M | 73.84M | 149M | 168M | 318M | |||||
Deferred Domestic Taxes | -135K | 2.82M | -120M | -103M | -109M | |||||
Deferred Foreign Taxes | -566K | 8.26M | -7.82M | -1.98M | -3.67M | |||||
Total Deferred Taxes | -701K | 11.08M | -128M | -105M | -112M | |||||
Normalized Net Income | 248M | 325M | 316M | 352M | 564M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Selling and Marketing Expenses | 235M | 288M | 349M | 381M | 397M | |||||
General and Administrative Expenses | 149M | 172M | 218M | 247M | 261M | |||||
Research And Development Expense From Footnotes | 294M | 382M | 520M | 629M | 693M | |||||
Net Rental Expense, Total | 13M | 14M | 16M | 16M | 14M | |||||
Stock-Based Comp., COGS (Total) | 32.54M | 41.09M | 56.6M | 59.72M | 57.97M | |||||
Stock-Based Comp., R&D Exp. (Total) | 63.54M | 83.84M | 142M | 173M | 186M | |||||
Stock-Based Comp., S&M Exp. (Total) | 40.57M | 56.83M | 87.51M | 90.86M | 90.18M | |||||
Stock-Based Comp., G&A Exp. (Total) | 48.35M | 52.88M | 66.23M | 70.27M | 103M | |||||
Total Stock-Based Compensation | 185M | 235M | 352M | 394M | 437M |
- Stock Market
- Equities
- VEEV Stock
- Financials Veeva Systems Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















